CAR-T cells : what intensivists need to know

Authors

  • Sandrine Valade 1. Service de Médecine Intensive et Réanimation, hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris, 1, avenue Claude Vellefaux, 75010, Paris, France. 2. Université de Paris, Paris, France.
  • Lara Zafrani 1. Service de Médecine Intensive et Réanimation, Hôpital Saint Louis, Assistance Publique des Hôpitaux de Paris, 1, avenue Claude Vellefaux, 75010, Paris, France. 2. Université de Paris, Paris, France

DOI:

https://doi.org/10.37051/mir-00064

Keywords:

intensive care, cytokine release syndrome, neurotoxicity syndrome, hematologic neoplasms

Abstract

Treatment with CAR-T cells represents an innovative therapeutic advance in patients with refractory hematological malignancies. Infectious complications must always be considered and empirically treated. Specific complications such as cytokine release syndrome (CRS) and neurotoxicity can be severe and patients often require intensive care unit admission. A close monitoring is necessary in these patients. While CRS treatment is based on the administration of anti-IL-6 receptor (tocilizumab) in mild forms, corticosteroids are recommended in severe CRS and/or neurotoxicity

Image

Downloads

Published

2021-08-23

How to Cite

Valade, S., & Zafrani, L. (2021). CAR-T cells : what intensivists need to know. Médecine Intensive Réanimation, 30(3), 247–256. https://doi.org/10.37051/mir-00064

Issue

Vol. 30 No. 3 (2021): Juillet-Septembre 2021

Section

Update

Categories

Most read articles by the same author(s)